Table 1.

Allocation strategies of COVID-19 vaccines and antivirals.

Strategy	Vaccine and antiviral allocation
Strategy 0	•No change to vaccination uptake recorded on 1 August 2021
Strategy 1: PV	•Vaccinate the never-vaccinated individuals only as much as possible (i.e. primary vaccination coverage of 70%, 80% and 90% in three scenarios)
Strategy 2: PV+AR	•Vaccinate the never-vaccinated individuals only as much as possible •Provide antivirals to 50% of symptomatic patients (assuming that the antivirals reduce their risk of hospitalisation by 50%)
Strategy 3: PV+AV+AR	•Vaccinate the never-vaccinated individuals as much as possible •Give an additional dose to only AZD1222 or CoronaVac vaccinees •Provide antivirals to 50% of the symptomatic patients
Strategy 4: PV+ selective AV+AR	•Vaccinate the never-vaccinated individuals as much as possible •Give an additional dose to all vaccinated individuals with PRNT50 titre lower than a certain threshold •Provide antivirals to 50% of the symptomatic patients
Strategy 5: PV+ universal AV+AR	•Vaccinate the never-vaccinated individuals as much as possible •Give an additional dose to all vaccinated individuals •Provide antivirals to 50% of the symptomatic patients